PACA and cabazitaxel for anti-cancer treatment

Number of patents in Portfolio can not be more than 2000

United States of America Patent

PATENT NO 11806330
APP PUB NO 20190298682A1
SERIAL NO

16366596

Stats

ATTORNEY / AGENT: (SPONSORED)

Importance

Loading Importance Indicators... loading....

Abstract

See full text

Described herein is an active ingredient encapsulated into poly (alkyl cyanoacrylate) nanoparticles and their use in anti-cancer treatments by intraperitoneal administration.

Loading the Abstract Image... loading....

First Claim

See full text

Family

Loading Family data... loading....

Patent Owner(s)

Patent OwnerAddress
OSLO UNIVERSITETSSYKEHUS HFP O BOX 4950 NYDALEN N-0424 OSLO N-0424
SINTEF TTO ASPOSTBOKS 4764 TORGARDEN TRONDHEIM N-7465

International Classification(s)

Inventor(s)

Inventor Name Address # of filed Patents Total Citations
Flatmark, Kjersti Blommenholm, NO 8 6
Fleten, Karianne Giller Oslo, NO 3 3
Johnsen, Heidi Trondheim, NO 13 8
Morch, Yrr Trondheim, NO 5 5
Schmid, Ruth Tiller, NO 18 143
Stenstad, Per Trondheim, NO 10 113
Sulheim, Einar Trondheim, NO 9 5

Cited Art Landscape

Load Citation

Patent Citation Ranking

Forward Cite Landscape

Load Citation

Maintenance Fees

Fee Large entity fee small entity fee micro entity fee due date
3.5 Year Payment $1600.00 $800.00 $400.00 May 7, 2027
7.5 Year Payment $3600.00 $1800.00 $900.00 May 7, 2031
11.5 Year Payment $7400.00 $3700.00 $1850.00 May 7, 2035
Fee Large entity fee small entity fee micro entity fee
Surcharge - 3.5 year - Late payment within 6 months $160.00 $80.00 $40.00
Surcharge - 7.5 year - Late payment within 6 months $160.00 $80.00 $40.00
Surcharge - 11.5 year - Late payment within 6 months $160.00 $80.00 $40.00
Surcharge after expiration - Late payment is unavoidable $700.00 $350.00 $175.00
Surcharge after expiration - Late payment is unintentional $1,640.00 $820.00 $410.00